Brief: Supernus Pharmaceuticals Q3 Product Sales USD 170.3 Million
04/11/2024 21:05
Nov 04 (Reuters) - Supernus Pharmaceuticals Q3 operating earnings USD 40.845 million. * Q3 adjusted revenue USD 130.6 million vs. IBES estimate USD 157.3 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing